Veerhealth Care has secured an export order worth ₹15.73 lakhs for the manufacture and supply of Gripe Water from an established buyer in Sudan. Announced on July 24, 2026, the deal represents the company’s first strategic entry into the Sudan market, expanding its global presence in the pediatric and wellness care segment. Management anticipates leveraging this initial order to build long-term relationships and capitalize on growing opportunities across the African region. The order carries no related-party interest, as confirmed by Managing Director Bhavin S. Shah.

The announcement was made under Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The buyer’s identity remains undisclosed due to confidential terms. The contract requires execution within 45 days, indicating a short-term fulfillment cycle typical for pharmaceutical supply agreements.

Order Details

The order value of ₹15,73,992 reflects a modest but strategically significant contract for Veerhealth Care. While the absolute value is small relative to large-cap pharmaceutical exports, it serves as a foothold for potential volume expansion in the African market. The absence of promoter or group company interest in the awarding entity ensures the transaction is at arm’s length, reinforcing compliance standards.

What the Numbers Show

The immediate execution window of 45 days suggests that inventory and logistics preparations are already underway or can be rapidly mobilized. For a niche product like Gripe Water, which targets infant colic and digestive discomfort, securing an international buyer indicates validated demand in emerging markets. This entry into Sudan may serve as a template for similar expansions in other African nations where pediatric healthcare infrastructure is growing. The lack of disclosed buyer details limits deeper analysis of customer concentration risk, but the non-related-party status mitigates governance concerns.

Veerhealth Care Limited has secured a new sample order worth ₹76.40 lakh from one of India's leading FMCG companies for skincare products. The order is scheduled for execution within 45 days and involves manufacturing goods under a new Maximum Retail Price (MRP) structure designed to facilitate brand promotion and market expansion for the client. This development supports the company's growth trajectory as it targets a total income of ₹105 crores with a PAT of ₹5–6 crores in FY26-27.

The buyer operates in the domestic and international markets within the 'personal and household care' segment and is part of a 125-year-old prominent business group. Veerhealth Care clarified that the promoter, promoter group, or group companies hold no interest in the entity awarding the order, and the transaction does not fall under related party transactions. The disclosure was submitted to BSE Limited on July 23, 2026.

Bhavin S. Shah, Managing Director of Veerhealth Care Limited, signed the regulatory filing. The company highlighted its position as one of India's fastest-growing listed Ayurvedic and cosmetic formulation manufacturers, operating under the brand Ayuveer. Veerhealth Care specializes in manufacturing pure vegetarian toothpaste and is among the few small-cap companies globally to have secured USFDA plant clearance.

Financial Outlook and Strategic Developments

Veerhealth Care provided forward-looking financial guidance, projecting a total income of ₹156 crores with a PAT of ₹9–10 crores in FY27-28. The company reported a book value per share of ₹11.46 for FY26, which is expected to increase substantially following the recent receipt of preferential warrant monies. Additionally, the company is in advanced stages of talks with one of India's largest hotel amenities suppliers, which has an Indo-Canadian joint venture.

Order Details

The following table outlines the key parameters of the order received by Veerhealth Care Limited: